Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures

References

• PeltolaJCoetzeeCJiménezFOnce-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trialEpilepsia200950340641419317886
   PubMed Web of Science ®Google Scholar
• Ben-MenachemEFalterUEfficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study GroupEpilepsia200041101276128311051122
   PubMed Web of Science ®Google Scholar
• CereghinoJJBitonVAbou-KhalilBDreifussFGauerLJLeppikILevetiracetam for partial seizures: results of a double-blind, randomized clinical trialNeurology200055223624210908898
   PubMed Web of Science ®Google Scholar
• ShorvonSDLöwenthalAJanzDBielenELoiseauPMulticenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study GroupEpilepsia20004191179118610999557
   PubMed Web of Science ®Google Scholar
• RouitsEBurtonIGuénoléETroenaruMMStockisASargentini-MaierMLPharmacokinetics of levetiracetam XR 500 mg tabletsEpilepsy Res2009842–322423119264451
   PubMed Web of Science ®Google Scholar
• NoyerMGillardMMatagneAHénichartJPWülfertEThe novel anti-epileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEur J Pharmacol199528621371468605950
   PubMed Web of Science ®Google Scholar
• KlitgaardHMatagneAGobertJWülfertEEvidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyEur J Pharmacol19983532–31912069726649
   PubMed Web of Science ®Google Scholar
• GoddardGVMcIntyreDCLeechCKA permanent change in brain function resulting from daily electrical stimulationExp Neurol19692532953304981856
   PubMed Web of Science ®Google Scholar
• VinogradovaLVvan RijnCMAnticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling modelEpilepsia20084971160116818397292
   PubMed Web of Science ®Google Scholar
• LöscherWHönackDRundfeldtCAntiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsyJ Pharmacol Exp Ther199828424744799454787
   PubMed Web of Science ®Google Scholar
• Ji-qunCIshiharaKNagayamaTSerikawaTSasaMLong-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugsEpilepsia20054691362137016146430
   PubMed Web of Science ®Google Scholar
• ZonaCNiespodzianyIMarchettiCKlitgaardHBernardiGMargineanuDGLevetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currentsSeizure200110427928611466024
   PubMed Web of Science ®Google Scholar
• LukyanetzEAShkrylVMKostyukPGSelective blockade of N-type calcium channels by levetiracetamEpilepsia200243191811879381
   PubMed Web of Science ®Google Scholar
• NiespodzianyIKlitgaardHMargineanuDGLevetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slicesNeurosci Lett20013061–25811403944
   PubMed Web of Science ®Google Scholar
• AngehagenMMargineanuDGBen-MenachemERönnbäckLHanssonEKlitgaardHLevetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neuronsNeuroreport200314347147512634506
   PubMed Web of Science ®Google Scholar
• NagarkattiNDeshpandeLSDeLorenzoRJLevetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in cultureNeurosci Lett2008436328929318406528
   PubMed Web of Science ®Google Scholar
• DesaullesEBouxOFeltzPCaffeine-induced Ca2+ release inhibits GABAA responsiveness in rat identified native primary afferentsEur J Pharmacol199120311371401797551
   PubMed Web of Science ®Google Scholar
• MargineanuDGKlitgaardHInhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugsPharmacol Res200042428128510987984
   PubMed Web of Science ®Google Scholar
• LynchBALambengNNockaKThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProc Natl Acad Sci U S A2004101269861986615210974
   PubMed Web of Science ®Google Scholar
• GillardMChatelainPFuksBBinding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant proteinEur J Pharmacol20065361–210210816556440
   PubMed Web of Science ®Google Scholar
• CrowderKMGuntherJMJonesTAAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)Proc Natl Acad Sci U S A19999626152681527310611374
   PubMed Web of Science ®Google Scholar
• KeppraXR [Package insert]Smyrna, GAUCB Pharma, Inc2008
   Google Scholar
• PatsalosPNClinical pharmacokinetics of levetiracetamClin Pharmacokinet2004431170772415301575
   PubMed Web of Science ®Google Scholar
• PatsalosPNPharmacokinetic profile of levetiracetam: toward ideal characteristicsPharmacol Ther2000852778510722121
   PubMed Web of Science ®Google Scholar
• BrockmöllerJThomsenTWittstockMCoupezRLochsHRootsIPharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function testsClin Pharmacol Ther200577652954115961984
   PubMed Web of Science ®Google Scholar
• GlauserTAMitchellWGWeinstockAPharmacokinetics of levetiracetam in infants and young children with epilepsyEpilepsia20074861117112217442002
   PubMed Web of Science ®Google Scholar
• PellockJMGlauserTABebinEMPharmacokinetic study of levetiracetam in childrenEpilepsia200142121574157911879369
   PubMed Web of Science ®Google Scholar
• BrowneTRSzaboGKLeppikIEJosephsEPazJBaltesEJensenCMAbsence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new techniqueJ Clin Pharmacol200040659059510868309
   PubMed Web of Science ®Google Scholar
• Ragueneau-MajlessiILevyRHMeyerhoffCLack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarinEpilepsy Res2001471–2556311673021
   PubMed Web of Science ®Google Scholar
• LevyRHRagueneau-MajlessiIBaltesERepeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteersEpilepsy Res2001462939911463510
   PubMed Web of Science ®Google Scholar
• Ragueneau-MajlessiILevyRHJanikFLevetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy womenEpilepsia200243769770212102671
   PubMed Web of Science ®Google Scholar
• GidalBEBaltèsEOtoulCPeruccaEEffect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trialsEpilepsy Res2005641–211115823510
   PubMed Web of Science ®Google Scholar
• PeruccaEGidalBEBaltèsEEffects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trialsEpilepsy Res2003531–2475612576167
   PubMed Web of Science ®Google Scholar
• GlauserTAAyalaREltermanRDDouble-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizuresNeurology200666111654166016641323
   PubMed Web of Science ®Google Scholar
• GlauserTAPellockJMBebinEMEfficacy and safety of levetiracetam in children with partial seizures: an open-label trialEpilepsia200243551852412027913
   PubMed Web of Science ®Google Scholar
• GrossoSFranzoniECoppolaGEfficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsySeizure200514424825315911359
   PubMed Web of Science ®Google Scholar
• LagaeLBuyseGCeulemansBClinical experience with levetiracetam in childhood epilepsy: an add-on and monotherapy trialSeizure2005141667115642504
   PubMed Web of Science ®Google Scholar
• CallenbachPMArtsWFten HoutenRAdd-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multicentre studyEur J Paediatr Neurol200812432132717950011
   PubMed Web of Science ®Google Scholar
• NoachtarSAndermannEMeyvischPLevetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizuresNeurology200870860761618285535
   PubMed Web of Science ®Google Scholar
• BerkovicSFKnowltonRCLeroyRFSchiemannJFalterULevetiracetam N01057 Study GroupPlacebo-controlled study of levetiracetam in idiopathic generalized epilepsyNeurology200769181751176017625106
   PubMed Web of Science ®Google Scholar
• SafdiehJHardenCLevetiracetam: past, present and futureFuture Medicine200614365371
   Google Scholar
• BrodieMJPeruccaERyvlinPBen-MenachemEMeenckeHJLevetiracetam Monotherapy Study GroupComparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsyNeurology200768640240817283312
   PubMed Web of Science ®Google Scholar
• AlsaadiTMShatzelAMarquezAVJorgensenJFariasSClinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up studySeizure200514213914215694569
   PubMed Web of Science ®Google Scholar
• AlsaadiTMKoopmansSAppersonMFariasSLevetiracetam monotherapy for elderly patients with epilepsySeizure2004131586014741184
   PubMed Web of Science ®Google Scholar
• AlsaadiTMThiemanCLevetiracetam monotherapy for newly diagnosed epilepsy patientsSeizure200312315415612651080
   PubMed Web of Science ®Google Scholar
• AlsaadiTMThiemanCZusmanEELevetiracetam monotherapy for adults with localization-related epilepsyEpilepsy Behav20023547147412609270
   PubMed Web of Science ®Google Scholar
• Abou-KhalilBBenefit-risk assessment of levetiracetam in the treatment of partial seizuresDrug Saf2005281087189016180937
   PubMed Web of Science ®Google Scholar
• FrenchJEdrichPCramerJAA systematic review of the safety profile of levetiracetam: a new antiepileptic drugEpilepsy Res2001471–2779011673023
   PubMed Web of Science ®Google Scholar
• BootsmaHPRickerLDiepmanLLevetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy centerEpilepsy Behav200710229630317317325
   PubMed Web of Science ®Google Scholar
• DepondtCYuenAWBellGSThe long term retention of levetiracetam in a large cohort of patients with epilepsyJ Neurol Neurosurg Psychiatry200677110110316361605
   PubMed Web of Science ®Google Scholar
• Abou-KhalilBSchaichLLong-term efficacy of levetiracetam for partial seizuresSeizure200514857758516280250
   PubMed Web of Science ®Google Scholar
• NicolsonALewisSASmithDFA prospective analysis of the outcome of levetiracetam in clinical practiceNeurology200463356857015304598
   PubMed Web of Science ®Google Scholar
• MulaMTrimbleMRYuenALiuRSSanderJWPsychiatric adverse events during levetiracetam therapyNeurology200361570470612963770
   PubMed Web of Science ®Google Scholar
• CramerJADe RueKDevinskyOEdrichPTrimbleMRA systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trialsEpilepsy Behav20034212413212697136
   PubMed Web of Science ®Google Scholar
• BrodtkorbEKleesTMNakkenKOLossiusRJohannessenSILevetiracetam in adult patients with and without learning disability: focus on behavioral adverse effectsEpilepsy Behav20045223123515123025
   PubMed Web of Science ®Google Scholar
• FerrendelliJAFrenchJLeppikIUse of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trialEpilepsy Behav20034670270914698704
   PubMed Web of Science ®Google Scholar
• CramerJALeppikIERueKDEdrichPKrämerGTolerability of levetiracetam in elderly patients with CNS disordersEpilepsy Res2003562–313514514642998
   PubMed Web of Science ®Google Scholar
• IsoherranenNSpiegelsteinOBialerMDevelopmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyloxo-pyrrolidine acetamide in a mouse model of teratogenicityEpilepsia200344101280128814510821
   PubMed Web of Science ®Google Scholar
• HuntSCraigJRussellALevetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy RegisterNeurology200667101876187917130430
   PubMed Web of Science ®Google Scholar
• TomsonTPalmRKällénKPharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactationEpilepsia20074861111111617381438
   PubMed Web of Science ®Google Scholar
• SilverJMShinCMcNamaraJOAntiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespyAnn Neurol19912943563631929206
   PubMed Web of Science ®Google Scholar
• SillsGJSeizures beget seizures: a lack of experimental evidence and clinical relevance fails to dampen enthusiasmEpilepsy Curr20077410310417694168
   PubMedGoogle Scholar
• DudekFEBertramEHStaleyKJAntiepileptogenesis therapy with levetiracetam: data from kindling versus status epilepticus modelsEpilepsy Curr200881283018265888
   PubMedGoogle Scholar
• LimDATaraporePChangESafety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot studyJ Neurooncol2009124 Epub ahead of print
   Web of Science ®Google Scholar
• WagnerGLWilmsEBVan DonselaarCAVechtChJLevetiracetam: preliminary experience in patients with primary brain tumoursSeizure200312858558614630498
   PubMed Web of Science ®Google Scholar
• GidalBEShethRDMagnusLHerbeuvalAFLevetiracetam does not alter body weight: analysis of randomized, controlled clinical trialsEpilepsy Res2003562–312112614642996
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• PullarTBirtwellAJWilesPGHayAFeelyMPUse of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times dailyClin Pharmacol Ther19884455405453180635
   PubMed Web of Science ®Google Scholar
• BialerMExtended-release formulations for the treatment of epilepsyCNS Drugs200721976577417696575
   PubMed Web of Science ®Google Scholar